Massivemarkets

RXRX

Recursion Pharmaceuticals, Inc. Class A Common Stock

Nasdaq · usd

$3.82+0.12 (+3.22%)
As of 2:23:54 PM EDT on Oct 26, 2026 · 15-minute delayed

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) trades at $3.82 (+3.22%) as of 2:23:54 PM EDT on Oct 26, 2026, +2.14% over the past month. Market cap is $1.98B, with 6.1 days to cover in short interest.

Stock performance

How Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock has performed from one day to one year, with its 52-week range.

+3.77%
+$0.14 over 1D
$3.66$3.72$3.78$3.844:00 AM7:00 AM9:25 AM11:55 AM2:20 PM$3.82
1D
+3.24%
1W
+5.82%
1M
+2.14%
YTD
-6.60%
1Y
-39.37%
52-wk range
$2.77 – $6.50

Key statistics

Today's trading snapshot for RXRX: day range, open, previous close, volume and market cap.

Day range
$3.64 – $3.86
Open
$3.71
Prev close
$3.70
Volume
11.54M
Market cap
$1.98B
Shares out
535.34M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Recursion Pharmaceuticals, Inc. Class A Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
36.17
P/B
2.17
P/FCF
—
ROE
-56.7%
ROA
-42.8%
Debt/Equity
0.02
Div yield
0.00%

As of Oct 23, 2026

8-K filings

Material corporate events Recursion Pharmaceuticals, Inc. Class A Common Stock has disclosed to the SEC on Form 8-K.

  • Significant contract awardOct 15, 2026

    The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments under the collaboration to $144 million to date. Recursion remains eligible for more than $300 million in additional milestones for this program, with an average of low double-digit royalties on net product sales if successfully commercialized.

  • Significant contract awardSep 21, 2026

    In consideration for the license, Tempus will pay the Company a non-refundable license fee of $12,000,000 in two installments of $6,000,000 each; the first due upon execution of the TxFM License Agreement and the other due on the first anniversary of the effective date.

  • Investor presentationAug 5, 2026

    On August 5, 2026, the Company released an updated corporate presentation to the investor section of the Company's website. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on August 5, 2026, the Company released a presentation made in connection with its L(earnings) call on August 5, 2026.

  • Annual meeting resultsJun 18, 2026

    Recursion Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders on June 17, 2026. At the Annual Meeting, the Company's stockholders voted on the following proposals... The stockholders elected as Class II directors the two individuals listed below... The advisory resolution to approve executive compensation... was approved... The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified.

  • Investor presentationMay 6, 2026

    On May 6, 2026, the Company released an updated corporate presentation to the investor section of the Company's website. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K.

RXRX short interest

How heavily RXRX is shorted: shares short, days to cover and average daily volume.

Days to cover
6.1
Short interest
157.94M
Avg volume
25.77M

As of · reported to FINRA twice monthly.

RXRX news

The latest news and headlines about Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX).

Frequently asked questions

What is the Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock price today?

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is trading at $3.82 (+3.22% on the day) as of 2:23:54 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Recursion Pharmaceuticals, Inc. Class A Common Stock?

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and…

What is the short interest in RXRX?

As of Sep 30, 2026, RXRX has 157.94M shares short and 6.1 days to cover.

What exchange is RXRX listed on?

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of RXRX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a RXRX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.